Alliqua Inc fka ALQA

[Trend22]

HPLF.. News today. A little move upward.

HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
(Business Wire 06/25 08:15:01)

Business Editors / Health/Medical Writers

BOSTON--(BUSINESS WIRE)----
HepaLife Technologies, Inc. (OTCBB: HPLF) (FWB: HL1) (WKN: 500625)
today announced that new data presented at an international influenza
research conference demonstrates that HepaLife's patented PBS-1 cell
line outperforms current cell technologies at replicating human
influenza virus inside its cells. The most important step towards the
production of a cell-culture based vaccine against a targeted virus is
the ability to efficiently grow the same virus in a cell substrate.

Data presented at the "Options for the Control of Influenza VI
Conference," June 17-23, 2007, in Toronto, Canada, compared human
influenza virus replication capabilities of several established cell
lines. HepaLife's PBS-1 cell line significantly outperformed today's
prevailing cell systems, including VERO (African green monkey kidney
cell), MDCK ("Martin-Darby Canine Kidney") and primary chick kidney
cells ("CEK").

(Click here to download HepaLife's PBS-1 cell line research
results: http://www.hepalife.com/Smith_et_al-2007_-_PBS1_Poster.pdf)

"I'm very proud of the efforts that our research team has made in
demonstrating the superiority of HepaLife's PBS-1 cells at an
international conference dedicated to identifying cutting-edge
solutions to influenza," commented Mr. Frank Menzler, President and
CEO of HepaLife Technologies, Inc. "I'm especially pleased that our
cell line is able to successfully grow targeted human influenza virus
where other leading commercial and academically-researched cells lines
have either failed to keep up, or are simply unable to do so."

According to test results, HepaLife's PBS-1 cells developed higher
influenza 'titers' -- or concentration of influenza -- than CEK cells.
In contrast, MDCK and VERO cells were unable to replicate virus and
produce comparable results. Importantly, the tested influenza strains
had not been previously adapted to any of the cell lines, including
PBS-1 cells.

Unlike VERO and MDCK cells, neither CEK cells nor HepaLife's PBS-1
require the need for exogenous proteases, such as Trypsin, therefore
eliminating an additional step in manufacturing. However, unlike CEK
cells, the PBS-1 cell line is less prone to dangerous contaminating
pathogens which are undesirable, disease-causing micro-organisms.

"Our patented PBS-1 cell line successfully produces more influenza
virus at higher concentrations than any other tested cell lines, and
is able to eliminate a cumbersome manufacturing step involving
exogenous proteases," explained Mr. Menzler. "Our cell line is able to
remain free of unwanted pathogens, and above all, can out-live and
outperform the only other tested cell line that registered any evident
influenza virus levels, the CEK."

CEK cells are a primary cell line, typically unable to survive
beyond five generations of growth, or 'passages'. HepaLife's PBS-1
cells are a continuous cell line which has already successfully lived
through hundreds of passages.

Importantly, scientists have discovered that the PBS-1 cell line
may also be suitable for isolating the influenza virus from
respiratory samples for diagnostic testing. According to research
findings, nineteen blind influenza virus received from human
respiratory samples were successfully identified as type-A influenza
using PBS-1 cells.

Entitled "High titer growth of human and avian influenza viruses
in an immortalized chick embryo cell line without the need for
exogenous proteases," this new data was presented by Kristen Smith
from Michigan State University, Department of Animal Science,
Molecular Pathogenesis Laboratory, East Lansing, Michigan.

"The success of our patented PBS-1 cell line for influenza vaccine
production alongside the parallel success of our patented PICM-19 cell
line for development of the world's first-of-its-kind artificial liver
device, clearly establishes HepaLife's position as an innovator in the
development of new cell-based technologies," concluded Mr. Frank
Menzler.

Recently, HepaLife's PICM-19 liver cell line for use in an
artificial liver device significantly outperformed the world's most
widely used human liver cell line, the HepG2-C3A. In tests designed to
measure a crucial function of the liver, HepaLife's PICM-19 cells
successfully synthesized 100% of the ammonia present, almost four
times more than HepG2-C3A.

The same tests also demonstrated that PICM-19 cells are able to
express high levels of cytochrome P-450 enzymes, a key liver-related
function in the detoxification of drugs and xenobiotics. In contrast,
HepG2-C3A showed very low or no detectable P450 activity at all.

(View HepaLife's April 10, 2007 press release and photographs:
PICM-19 cells mimic liver's responses; significantly outperform most
widely-used liver cell line:
http://www.hepalife.com/20070410-1.html.php)

In previous weeks, HepaLife's proprietary bioreactor system, the
main mechanical component of its patented bioartificial liver device,
successfully replicated the liver's key function -- removal of toxic
ammonia and synthesis of urea. Researchers consider this ability vital
to successfully replicating the human liver's function in an
artificial liver device.

(View HepaLife's April 30, 2007 press release: HepaLife achieves
major milestone in development of artificial liver device:
http://www.hepalife.com/20070430-1.html.php)

ABOUT HEPALIFE TECHNOLOGIES, INC.

HepaLife Technologies, Inc. (OTCBB: HPLF - News; FWB: HL1) (WKN:
500625) is a biotechnology company focused on the identification and
development of cell-based technologies and products.

Current cell-based technologies under development by HepaLife
include 1) the first-of-its-kind artificial liver device, 2)
proprietary in-vitro toxicology and pre-clinical drug testing
platforms, and 3) novel cell-culture based vaccine production to
protect against the spread of influenza viruses among humans,
including potentially the high pathogenicity H5N1 virus.

For additional information, please visit www.hepalife.com.

To receive future press releases via email, please visit:
http://www.hepalife.com/alerts.php

To view the full HTML text of this release, please visit:
http://www.hepalife.com/20070625-1.html.php

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a
solicitation of an offer for the purchase or sale of any securities.
This release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although the Company believes that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, it can give no
assurance that such expectations and assumptions will prove to have
been correct. Forward-looking statements, which involve assumptions
and describe our future plans, strategies, and expectations, are
generally identifiable by use of the words "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend," or
"project" or the negative of these words or other variations on these
words or comparable terminology. The reader is cautioned not to put
undue reliance on these forward-looking statements, as these
statements are subject to numerous factors and uncertainties,
including but not limited to adverse economic conditions, intense
competition, lack of meaningful research results, entry of new
competitors and products, adverse federal, state and local government
regulation, inadequate capital, unexpected costs and operating
deficits, increases in general and administrative costs, termination
of contracts or agreements, technological obsolescence of the
Company's products, technical problems with the Company's research and
products, price increases for supplies and components, litigation and
administrative proceedings involving the Company, the possible
acquisition of new businesses or technologies that result in operating
losses or that do not perform as anticipated, unanticipated losses,
the possible fluctuation and volatility of the Company's operating
results, financial condition and stock price, losses incurred in
litigating and settling cases, dilution in the Company's ownership of
its business, adverse publicity and news coverage, inability to carry
out research, development and commercialization plans, loss or
retirement of key executives and research scientists, changes in
interest rates, inflationary factors, and other specific risks. We
currently have no commercial products intended to diagnose, treat,
prevent or cure any disease. The statements contained in this press
release regarding our on going research and development and the
results attained by us to-date have not been evaluated by the Food and
Drug Administration. There can be no assurance that further research
and development, and /or whether clinical trial results, if any, will
validate and support the results of our preliminary research and
studies. Further, there can be no assurance that the necessary
regulatory approvals will be obtained or that HepaLife will be able to
develop commercially viable products on the basis of its technologies.
In addition, other factors that could cause actual results to differ
materially are discussed in the Company's most recent Form 10-Q and
Form 10-K filings with the Securities and Exchange Commission. These
reports and filings may be inspected and copied at the Public
Reference Room maintained by the U.S. Securities & Exchange Commission
at 100 F Street, N.E., Washington, D.C. 20549. You can obtain
information about operation of the Public Reference Room by calling
the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S.
Securities & Exchange Commission also maintains an Internet site that
contains reports, proxy and information statements, and other
information regarding issuers that file electronically with the U.S.
Securities & Exchange Commission at http://www.sec.gov. The Company
makes no commitment to publicly release the results of any revisions
to these forward looking statements that may be made to reflect the
events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events.



KEYWORD: NORTH AMERICA MASSACHUSETTS UNITED STATES CANADA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL TRADE SHOW
SOURCE: HepaLife Technologies, Inc.


CONTACT INFORMATION:
HepaLife Technologies, Inc.
Shareholder Communications
Ms. Laura Rivers-Bowerman, 800-518-4879


S.BW HPLF HL1 HEALT.BW BIOTC.BW PHARM.BW TRADE.BW MA.BW